BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
QuintilesIMS
Queensland Health
Novartis
Federal Trade Commission
Farmers Insurance
Express Scripts
AstraZeneca
Accenture
Medtronic

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,338,485

« Back to Dashboard

Summary for Patent: 8,338,485
Title:Compositions for the treatment of CNS-related conditions
Abstract: The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
Inventor(s): Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, NV)
Assignee: Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Application Number:13/536,588
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,338,485

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Forest Labs Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-003 Jul 18, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Forest Labs Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-001 Dec 23, 2014 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Forest Labs Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-004 Jul 18, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Forest Labs Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-002 Dec 23, 2014 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,338,485

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,426,472 Method and composition for administering an NMDA receptor antagonist to a subject ➤ Subscribe
8,338,486 Methods for the treatment of CNS-related conditions ➤ Subscribe
2,012,045,508 ➤ Subscribe
8,283,379 Methods and compositions for the treatment of CNS-related conditions ➤ Subscribe
8,168,209 Method and composition for administering an NMDA receptor antagonist to a subject ➤ Subscribe
8,329,752 Composition for administering an NMDA receptor antagonist to a subject ➤ Subscribe
8,580,858 Compositions for the treatment of CNS-related conditions ➤ Subscribe
8,173,708 Method and composition for administering an NMDA receptor antagonist to a subject ➤ Subscribe
2,012,058,182 ➤ Subscribe
7,619,007 Method and composition for administering an NMDA receptor antagonist to a subject ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,338,485

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2008520736 ➤ Subscribe
Japan 2009173669 ➤ Subscribe
South Korea 20070112763 ➤ Subscribe
South Korea 101301429 ➤ Subscribe
South Korea 20070116996 ➤ Subscribe
South Korea 101406456 ➤ Subscribe
South Korea 20060124731 ➤ Subscribe
Mexico 2007006120 ➤ Subscribe
Mexico 2007012374 ➤ Subscribe
Russian Federation 2007122410 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Deloitte
Express Scripts
US Army
Chubb
Julphar
Fish and Richardson
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot